Antibody constant region variant

Patent Citations (386)

Non-Patent Literature (551)

• Amgen vs Sanofi and Regeron (Case: 17-1480 Document: 176 Filed: Feb. 6, 2018).Examiner
• Batra et al., “Pharmacokinetics and biodistribution of genetically engineered antibodies,” Curr Opin Biotechnol., Dec. 2002;13(6):603-8.Applicant
• Smolen et al., “Interleukin-6: a new therapeutic target,” Arthritis Res Ther., 2006;8 Suppl 2:S5. Epub Jul. 28, 2006.Applicant
• Dall'Acqua et al., “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences,” J. Immunol., Nov. 1, 2002; 169(9):5171-80.Applicant
• Gramer et al., “Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches,” MAbs., Nov.-Dec. 2013; 5(6):962-73. doi: 10.4161/mabs.26233. Epub Aug. 22, 2013.Applicant
• Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” MAbs., Nov.-Dec. 2012; 4(6):653-63. doi: 10.4161/mabs.21379. Epub Aug. 27, 2012.Applicant
• Labrijn et al., “Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange,” Pro Natl Acad Sci U S A., Mar. 26, 2013; 110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub Mar. 11, 2013.Applicant
• Labrijn et al., “Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength,” J Immunol., Sep. 15, 2011; 187(6):3238-46. doi: 10.4049/jimmunol.1003336. Epub Aug. 12, 2011.Applicant
• McPhee et al., “Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation,” Proc Natl Acad Sci U S A., Oct. 15, 1996; 93(21):11477-81.Applicant
• Rispens et al., “Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange,” J Biol Chem., Feb. 28, 2014; 289(9):6098-109. doi: 10.1074/jbc.M113.541813. Epub Jan. 14, 2014.Applicant
• Schaefer et al., “Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies,” Proc Natl Acad Sci U S A., Jul. 5, 2011; 108(27):11187-92. doi: 10.1073/pnas.1019002108. Epub Jun. 20, 2011.Applicant
• Schuurman et al., “Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites,” Immunology, Aug. 1999; 97(4):693-8.Applicant
• Schuurman et al., “The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds,” Mol Immunol., Jan. 2001; 38(1):1-8.Applicant
• Van Der Neut Kolfschoten et al., “Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange,” Science, Sep. 14, 2007; 317(5844):1554-7.Applicant
• Ward et al., “Effects of engineering complementary charged residues into the hydrophobic subunit interface of tyrosyl-tRNA synthetase. Appendix: Kinetic analysis of dimeric enzymes that reversibly dissociate into inactive subunits,” Biochemistry, Jun. 30, 1987; 26(13):4131-8.Applicant
• U.S. Appl. No. 15/263,617, filed Sep. 13, 2016, Igawa et al.Applicant
• Berglund et al., “The epitope space of the human proteome,” Protein Sci., Apr. 2008;17(4):606-13.Applicant
• Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J Mol Biol., Nov. 5, 1999;293(4):865-81.Applicant
• Holm et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Mol Immunol., Feb. 2007;44(6):1075-84.Applicant
• Examiner Michael D. Allen, USPTO Non-Final Office Action in U.S. Appl. No. 13/582,073, dated Aug. 19, 2016, 20 pages.Applicant
• U.S. Appl. No. 15/263,617, Igawa et al., Sep. 13, 2016.Applicant
• Brenner et al., “Errors in genome annotation,” Trends in Genetics, Apr. 1999;15:132-133.Applicant
• Choi et al., “Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening,” PLoS One, Dec. 16, 2015;10(12):e0145349. doi: 10.1371/journal.pone.0145349. eCollection 2015.Applicant
• Coloma et al., “Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1→6) dextran antibody,” J Immunol., Feb. 15, 1999;162(4):2162-70.Applicant
• Diaz et al., “Effects of engineering charged amino acids in the CH3 domains on antibody heavy chain dimerization,” Philippine Science Letters. 2011;4(1):48-55.Applicant
• Ejima et al, “Effects of Acid Exposure on the Conformation, Stability, and Aggregation of Monoclonal Antibodies,” Proteins. Mar. 1, 2007;66(4):954-62.Applicant
• Gen Bank Accession No. AAG00910.2, “recombinant IgG2 heavy chain, partial [Homo sapiens],” May 14, 2001, 1 page.Applicant
• Hird et al., “Tumour localisation with a radioactively labelled reshaped human monoclonal antibody,” Br J Cancer, Nov. 1991;64(5):911-4.Applicant
• Hong et al., “Enhanced cellular uptake and transport of polyclonal immunoglobulin G and fab after their cationization,” J Drug Target., 2000;8(2):67-77.Applicant
• Li et al., “Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions,” Immunology, Dec. 2005;116(4):487-98.Applicant
• Marshall et al., “Rational design and engineering of therapeutic proteins,” Drug Discov Today, Mar. 1, 2003;8(5):212-21.Applicant
• Newman et al, “Modification of the Fc Region of a Primatized IgG Antibody to Human CD4 Retains Its Ability to Modulate CD4 Receptors but Does Not Deplete CD4 T Cells in Chimpanzees,” Clin Immunol. Feb. 2001;98(2):164-74.Applicant
• Pardridge et al., “Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization,” J Pharm Sci., Aug. 1995;84(8):943-8.Applicant
• Reimann et al., “A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties,” AIDS Res Hum Retroviruses, Jul. 20, 1997;13(11):933-43.Applicant
• Roopenian et al., “FcRn: the neonatal Fc receptor comes of age,” Nat Rev. Immunol., Sep. 2007;7(9):715-25.Applicant
• Sarkar et al., “Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching”, Nat Biotechnol., Sep. 2002;20(9):908-13. Epub Aug. 5, 2002.Applicant
• Sharifi et al., “Improving monoclonal antibody pharmacokinetics via chemical modification,” Q J Nucl Med., Dec. 1998;42(4):242-9.Applicant
• Smith et al., “The challenges of genome sequence annotation or ‘the devil is in the details’,” Nature Biotechnology, Nov. 1997;15:1222-1223.Applicant
• Tabrizi et al., “Elimination mechanisms of therapeutic monoclonal antibodies,” Drug Discov Today, Jan. 2006;11(1-2):81-8.Applicant
• Verhoeyen et al., “Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody,” Immunology, Mar. 1993;78(3):364-70.Applicant
• Verhoeyen et al., “Monoclonal Antibodies in Clinical Oncology,” 1991, Edited by AA Epenetos, Chapter 5, pp. 37-43, Chapman and Hall.Applicant
• Abe et al., “Purification of monoclonal antibodies with light-chain heterogeneity produced by mouse hybridomas raised with NS-1 myelomas: application of hydrophobic interaction high-performance liquid chromatography,” J. Biochem. Biophys. Methods, 27:215-227 (1993).Applicant
• Adams et al., “Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab,” Cancer Immunol. Immunother., 55:717-727 (2006).Applicant
• Algonomics—Tripole® applications [online] Retrieved from the Internet on Feb. 29, 2012: http://web.archive.org/web20090221052902/http://www.algonomics.com/proteinengineering/tripole_applications.php, 2 pages (Feb. 21, 2009).Applicant
• Allard et al., “Antigen binding properties of highly purified bispecific antibodies,” Mol Immunol., Oct. 1992; 29 (10):1219-27.Applicant
• Allen et al., “Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase,” Mol. Cell. Biol., 22(2):599-613 (2002).Applicant
• Allen et al., “Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis,” Biochemistry, 48(17):3755-66 (2009).Applicant
• Almagro et al., “Humanization of antibodies,” Front Biosci., 13:1619-33 (2008).Applicant
• Amersham Biosciences, “Affinity Chromatography: Principles and Methods,” Edition AD, pp. 16-18, 137 (2002).Applicant
• Amersham Biosciences, “Protein Purification Handbook,” Edition AC, 98 pages (2001).Applicant
• Armour et al., “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur. J. Immunol., 29(8):2613-24 (1999).Applicant
• Aslan et al., “Engineering a novel, stable dimeric streptavidin with lower isoelectric point,” J. Biotechnol., 128(2):213-25 (2007).Applicant
• Atwell et al., “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library,” J. Mol. Biol., 270:26-35 (1997).Applicant
• Baerga-Ortiz et al., “Two different proteins that compete for binding to thrombin have opposite kinetic and thermodynamic profiles,” Protein Sci., 13(1):166-76 (2004).Applicant
• Baker et al., “Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling,” Immunity, 13:475-484 (2000).Applicant
• Bartelds et al., “Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis,” Ann Rheum. Dis., 66(7):921-6 (2007).Applicant
• Bayry et al., “Immuno affinity purification of foot and mouth disease virus type specific antibodies using recombinant protein adsorbed to polystyrene wells,” J. Virol. Methods, 81:21-30 (1999).Applicant
• Bellosta et al., “Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation,” Oncogene., 15(20):2387-97 (1997).Applicant
• Bender et al., “Immunogenicity, efficacy and adverse events of adalimumab in RA patients,” Rheumatol. Int., 27(3):269-74 (2007).Applicant
• Bendig, “Humanization of rodent monoclonal antibodies by CDR grafting,” Methods: A Comparison to Methods in Enzymology, 8:83-93 (1995).Applicant
• Bian et al., “Discovery of promiscuous HLA-II-restricted T cell epitopes with Tepitope,” Methods, 34(4):468-75 (2004).Applicant
• Bilsborough, “IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis,” J. Allergy Clin. Immunol., 117(2):418-25 (2006).Applicant
• Binz et al., “Engineering novel binding proteins from nonimmunoglobulin domains,” Nat. Biotechnol., 23:1257-68 (2005).Applicant
• Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science, 247:1306-1310 (1990).Applicant
• Branden and Tooze, “Recognition of Foreign Molecules by the Immune System,” Introduction to Protein Structure, 2d Ed., Garland Publishing, pp. 299-323 (1999).Applicant
• Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?,” J. Immunol., 156(9):3285-91 (1996).Applicant
• Budagian et al., “A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control,” EMBO J., 24(24):4260-70 (2005).Applicant
• Burges et al., “Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study,” Clin. Cancer Res., 13(13):3899-905 (2007).Applicant
• Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,” J. Cell. Biol., 111:2129-2138 (1990).Applicant
• Calbiochem® Buffers, “A guide for the preparation and use of buffers in biological systems,” by Chandra Mohan, Ph.D., Copyright© 2003 EMD Biosciences, Inc., an Affiliate of Merck KGaA, Darmstadt, Germany, 37 pages.Applicant
• Carter, “Bispecific human IgG by design,” J. Immunol. Methods, 248:7-15 (2001).Applicant
• Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem Biophys Res Commun., Jul. 18, 2003;307:198-205.Applicant
• Chamow et al., “A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells,” J. Immunol., 153(9):4268-80 (1994).Applicant
• Chappel et al., “Identification of a secondary Fc gamma RI binding site within a genetically engineered human IgG antibody,” J Biol Chem., Nov. 25, 1993;268(33):25124-31.Applicant
• Chappel et al., “Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies,” Proc Natl Acad Sci U S A., Oct. 15, 1991;88(20):9036-40.Applicant
• Chau et al., “HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor,” Transplantation, 71(7):941-50 (2001).Applicant
• Chen et al., “Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen,” J. Exp. Med., 176(3):855-66 (1992).Applicant
• Chen et al., “Defective secretion of an immunoglobulin caused by mutations in the heavy chain complementarity determining region 2,” J. Exp. Med., 180(2):577-86 (1994).Applicant
• Chien et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism,” Proc. Natl. Acad. Sci. U.S.A., 86(14):5532-6 (1989).Applicant
• Chirino et al., “Minimizing the immunogenicity of protein therapeutics,” Drug Discov. Today., 9(2):82-90 (2004).Applicant
• Chu et al., “Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures,” Pharm. Res., 24(6):1145-56 (2007).Applicant
• Chung et al., “Expression of the proto-oncogene Axl in renal cell carcinoma,” DNA Cell Biol., 22(8):533-40 (2003).Applicant
• Cole et al., “Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells,” J. Immunol., 159(7):3613-21 (1997).Applicant
• Comper and Glasgow, “Charge selectivity in kidney ultrafiltration,” Kidney Int., 47:1242-51 (1995).Applicant
• Cordoba et al., “Non-enzymatic hinge region fragmentation of antibodies in solution,” J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 818(2):115-21 (2005).Applicant
• Couto et al., “Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization,” Cancer Research, 55:1717-1722 (1995).Applicant
• Craven et al., “Receptor tyrosine kinases expressed in metastatic colon cancer,” Int. J. Cancer, 60(6):791-7 (1995).Applicant
• Dall'Acqua et al., “Antibody humanization by framework shuffling,” Methods, 36(1):43-60 (2005).Applicant
• Dall'Acqua et al., “Modulation of the effector functions of a human IgG1 through engineering of its hinge region,” J. Immunol., 177(2):1129-38 (2006).Applicant
• Damschroder et al., “Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties,” Mol. Immunol., 44(11):3049-60 (2007).Applicant
• Datta-Mannan et al., “Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor,” J Biol Chem., 282(3):1709-17 (2007).Applicant
• Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,” Immunotechnology, 2(3):169-79 (1996).Applicant
• De Pascalis et al., “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,” J. Immunol., 169(6):3076-84 (2002).Applicant
• Deen et al., “Structural determinants of glomerular permeability,” Am. J. Physiol. Renal. Physiol., 281:F579-F596 (2001).Applicant
• De Groot et al., “De-immunization of therapeutic proteins by T-cell epitope modification,” Dev. Biol. (Basel), 122:171-94 (2005).Applicant
• Del Rio et al., “An Engineered Penicillin Acylase with Altered Surface Charge Is More Stable in Alkaline pH,” Ann. NY Acad. Sci., 799:61-64 (1996).Applicant
• Deng et al., “An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis,” Blood, 92:1981-88 (1998).Applicant
• Dhiman et al., “Gene expression microarrays: a 21st century tool for directed vaccine design,” Vaccine, 20(1-2):22-30 (2001).Applicant
• Dillon et al., “Structural and functional characterization of disulfide isoforms of the human IgG2 subclass,” J. Biol. Chem., 283(23):16206-15 (2008).Applicant
• Dillon et al., “Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice,” Nat. Immunol., 5(7):752-760 (2004).Applicant
• Diveu et al., “GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor,” J. Biol. Chem., 278(50):49850-49859 (2003).Applicant
• Dumont et al., “Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics,” BioDrugs., 20(3):151-60 (2006).Applicant
• Elliott et al., “Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies,” J. Biol. Chem., 271(40):24691-7 (1996).Applicant
• Ewert et al., “Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering,” Methods, 34:184-199 (2004).Applicant
• Fridell et al., “GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells,” J. Biol. Chem., 273(12):7123-6 (1998).Applicant
• Fujii, “Antibody affinity maturation by random mutagenesis,” Methods Mol. Biol., 248:345-59 (2004).Applicant
• Gerstner et al., “Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody,” J. Mol. Biol., 321(5):851-62 (2002).Applicant
• Gessner et al., “The IgG Fc receptor family,” Ann Hematol., 76(6):231-48 (1998).Applicant
• Ghetie and Ward, “FcRn: the MHC class I-related receptor that is more than an IgG transporter,” Immunol. Today, 18:592-598 (1997).Applicant
• Ghetie et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nat. Biotechnol., 15:637-640 (1997).Applicant
• Ghetie et al., “Multiple roles for the major histocompatibility complex class I- related receptor FcRn,” Annu. Rev. Immunol., 18:739-766 (2000).Applicant
• Gobburu et al., “Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys,” J. Pharmacol. Exp. Ther., 286:925-930 (1998).Applicant
• Goode et al., “The glomerular basement membrane charge-selectivity barrier: an oversimplified concept?,” Nephrol. Dial. Transplant., 11:1714-16 (1996).Applicant
• Goruppi et al., “Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts,” Mol. Cell Biol., 17(8):4442-53 (1997).Applicant
• Graves et al., “Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody,” Clin. Cancer Res., 5:899-908 (1999).Applicant
• Greenwood et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immunol., May 1993;23(5):1098-104.Applicant
• Griffin et al., “Analysis of heavy and light chain sequences of conventional camelid antibodies from Camelus dromedarius and Camelus bactrianus species,” J Immunol Methods, Mar. 2014;405:35-46. doi: 10.1016/j.jim.2014.01.003. Epub Jan. 18, 2014.Applicant
• Gunasekaran et al., “Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG,” J. Biol. Chem., 285(25):19637-46 (2010).Applicant
• Gupta et al., “Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates,” J. Biochem. Biophys. Methods, 51:203-216 (2002).Applicant
• Gussow et al., “Humanization of monoclonal antibodies,” Methods Enzymol., 203:99-121 (1991).Applicant
• Guyre et al., “Increased potency of Fc-receptor-targeted antigens,” Cancer Immunol. Immunother., 45(3-4):146-8 (1997).Applicant
• Haagen et al., “Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic,” Cancer Immunol Immunother., Dec. 1994;39(6):391-6.Applicant
• Hafizi et al., “Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin,” Biochem. Biophys. Res. Commun., 299(5):793-800 (2002).Applicant
• Hafizi et al., “Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases,” Cytokine Growth Factor Rev., 17(4):295-304 (2006).Applicant
• Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, Jun. 3, 1993;363(6428):446-8.Applicant
• Hanes et al., “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,” Nat. Biotechnol., 18(12):1287-1292 (2000).Applicant
• Hanson et al., “Catalytic antibodies and their applications,” Curr. Opin. Biotechnol., 16:631-636 (2005).Applicant
• He et al., “Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin,” J. Immunol., 160:1029-35 (1998).Applicant
• Hinton et al., “An engineered human IgG1 antibody with longer serum half-life,” J. Immunol., Jan. 1, 2006;176:346-56.Applicant
• Hinton et al., “Engineered human IgG antibodies with longer serum half-lives in primates,” J. Biol. Chem., 279(8):6213-6 (2004).Applicant
• Holland et al., “Multiple roles for the receptor tyrosine kinase axl in tumor formation,” Cancer Res., Oct. 15, 2005;65(20):9294-303.Applicant
• Holt et al., “Domain antibodies: proteins for therapy,” Trends Biotechnol., 21(11):484-90 (2003).Applicant
• Hombach et al., “A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo,” Int J Cancer, 55:830-6 (1993).Applicant
• Hwang et al., “Use of human germline genes in a CDR homology-based approach to antibody humanization,” Methods., 36(1):35-42 (2005).Applicant
• Igawa et al., “VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody,” Protein Eng Des Sel., Aug. 2010;23(8):667-77. doi: 10.1093/protein/gzq034. Epub Jun. 24, 2010.Applicant
• Igawa et al., “Engineering the variable region of therapeutic IgG antibodies,” MAbs, 3(3):243-52 (2011).Applicant
• Igawa et al., “Reduced elimination of IgG antibodies by engineering the variable region,” Protein Eng. Des. Sel., 23(5):385-92 (2010).Applicant
• Igawa et al., “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization,” Nat. Biotechnol., 28(11):1203-7 (2010).Applicant
• IMGT Scientific charts depicting the correspondence between Eu and Kabat numberings for the human IgG constant region, created May 17, 2001 and last updated Aug. 13, 2014.Applicant
• Ito et al., “The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values,” FEBS Lett., 309:85-88 (1992).Applicant
• Ito et al., “Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around Chernobyl,” Thyroid., 12(11):971-5 (2002).Applicant
• Jackman et al., “Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling,” J Biol Chem., Jul. 2, 2010;285(27): 20850-9. doi: 10.1074/jbc.M110.113910. Epub May 5, 2010.Applicant
• Jain et al., “Engineering antibodies for clinical applications,” Trends Biotechnol., 25(7):307-16 (2007).Applicant
• Jefferis et al., “Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation,” Immunol. Lett., 44(2-3):111-7 (1995).Applicant
• Jendeberg et al., “Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A,” J. Immunol. Methods., 201(1):25-34 (1997).Applicant
• Johnson et al., “Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain,” Anal. Biochem., 360(1):75-83 (2007).Applicant
• Jones et al., “Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII,” Thromb. Haemost., 3(5):991-1000 (2005).Applicant
• Ju et al., “Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis,” Proc. Natl. Acad. Sci. U.S.A., 88:2658-2662 (1991).Applicant
• Kabat et al., Sequence of Proteins of Immunological Interest, 5th Edition 1991, p. 690 and p. 693.Applicant
• Kai et al., “Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor,” Nat. Biotechnol., 26(2):209-11 (2008).Applicant
• Kashmiri et al., “Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49,” Hybridoma, 14:461-473 (1995).Applicant
• Katayose et al., “MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth,” Cancer Res., 56(18):4205-12 (1996).Applicant
• Kenanova et al., “Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments,” Cancer Res., Jan. 15, 2005;65(2):622-31.Applicant
• Khawli et al., “Improved tumor localization and radioimaging with chemically modified monoclonal antibodies,” Cancer Biother. Radiopharm., 11:203-215 (1996).Applicant
• Kim et al., “Antibody Engineering for the Development of Therapeutic Antibodies,” Mol. Cells, 20:17-29 (2005).Applicant
• Kim et al., “Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-tac monoclonal antibody labeled with 99mTc,” Bioconjugate Chem., 10:447-453 (1999).Applicant
• Kim et al., “Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents,” Nucl. Med. Biol., 29:795-801 (2002).Applicant
• Kim et al., “Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn,” Eur. J. Immunol., Sep. 1999;29(9):2819-25.Applicant
• Kobayashi et al., “A monoclonal antibody specific for a distinct region of hen egg-white lysozyme,” Mol. Immunol., 19:619-30 (1982).Applicant
• Kobayashi et al., “The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points,” Cancer Res., 59:422-430 (1999).Applicant
• Komissarov et al., “Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction,” J. Biol. Chem., 272(43):26864-70 (1997).Applicant
• Kranenborg et al., “Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma,” Cancer Res., 55:5864s-5867s (1995).Applicant
• Krauss et al., “Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme,” Br. J. Cancer, 90:1863-70 (2004).Applicant
• Kufer et al., “A revival of bispecific antibodies,” Trends Biotechnol., 22(5):238-44 (2004).Applicant
• Kurfis et al., “Role of Arg182 in the second extracellular loop of angiotensin II receptor AT2 in ligand binding,” Biochem. Biophys. Res. Commun., 263:816-819 (1999).Applicant
• Kreutz et al., “Efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography,” J. Chromatogr. B, 714:161-170 (1998).Applicant
• Lansdorp et al., “Purification and analysis of bispecific tetrameric antibody complexes,” Mol. Immunol., 27:659-666 (1990).Applicant
• Lay et al., “Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL,” Cancer Res., 67(8):3878-87 (2007).Applicant
• Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,” Mol. Cell. Biol., 8:1247-1252 (1988).Applicant
• Lebégue et al., “Production and characterization of hybrid monoclonal antibodies with IgG1/IgG3 double isotype,” C R Acad Sci III., 1990;310(9):377-82.Applicant
• Leong et al., “Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation,” Cytokine, 16(3):106-19 (2001).Applicant
• Levin et al., “Optimizing the affinity and specificity of proteins with molecular display,” Mol. Biosyst., 2(1):49-57 (2006) (Epub Nov. 8, 2005).Applicant
• Lin et al., “Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor,” J Pharmacol Exp Ther., 288(1):371-8 (1999).Applicant
• Lindhofer et al., “Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas,” J. Immunol., 155:219-225 (1995).Applicant
• Liu et al., “Heterogeneity of monoclonal antibodies,” J. Pharm. Sci., 97(7):2426-47 (2008).Applicant
• Lloyd et al., “The production of a bispecific anti-CEA, anti-hapten (4-amino-phthalate) hybrid-hybridoma,” J Natl Med Assoc., Oct. 1991;83(10):901-4.Applicant
• Lobo et al., “Antibody pharmacokinetics and pharmacodynamics,” J. Pharm. Sci., 93:2645-68 (2004).Applicant
• Lund et al., “Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I,” Eur. J. Biochem., 267(24):7246-57 (2000).Applicant
• MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J. Mol. Biol., 262:732-45 (1996).Applicant
• Maeda et al., “pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes,” J. Control Release, 82(1):71-82 (2002).Applicant
• Maini et al., “Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate,” Arthritis Rheum., 54(9):2817-29 (2006).Applicant
• Male et al., “Antibodies” Immunology, 7th Edition (2006), published by Elsevier Ltd., pp. 59-86.Applicant
• Manz et al., Bioanalytical Chemistry, World Scientific Publishing Co. (2003).Applicant
• Manzke et al., “Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography,” J. Immunol. Methods, 1997;208:65-73.Applicant
• Mariuzza et al., “The structural basis of antigen-antibody recognition,” Annu. Rev. Biophys. Chem., 16:139-59 (1987).Applicant
• Marks et al., “By-passing immunization: building high affinity human antibodies by chain shuffling,” Biotechnology (N.Y.), 10(7):779-83 (1992).Applicant
• Marti et al., “Inverse electrostatic effect: electrostatic repulsion in the unfolded state stabilizes a leucine zipper,” Biochemistry, 43(39):12436-47 (2004).Applicant
• Martin et al., “Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding,” Mol. Cell, 7:867-877 (2001).Applicant
• Martinez et al., “Disulfide connectivity of human immunoglobulin G2 structural isoforms,” Jul. 15, 2008;47(28):7496-508. doi: 10.1021/bi800576c. Epub Jun. 13, 2008.Applicant
• Marvin et al., “Recombinant approaches to IgG-like bispecific antibodies,” Acta. Pharmacol. Sin., 26:649-658 (2005).Applicant
• Marvin et al., “Redesigning an antibody fragment for faster association with its antigen,” Biochemistry, 42:7077-83 (2003).Applicant
• Maxfield et al., “Endocytic recycling,” Nat. Rev. Mol. Cell Biol., 5(2):121-32 (2004).Applicant
• Maynard et al., “Antibody engineering,” Annu. Rev. Biomed. Eng., 2:339-76 (2000).Applicant
• McCloskey et al., “GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl,” J. Biol. Chem., 272(37):23285-91 (1997).Applicant
• Medesan et al., “Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1,” J Immunol., Mar. 1, 1997;158(5):2211-7.Applicant
• Merchant et al., “An efficient route to human bispecific IgG,” Nat. Biotechnol., 16:677-681 (1998).Applicant
• Meric et al., “Expression profile of tyrosine kinases in breast cancer,” Clin. Cancer Res., 8(2):361-7 (2002).Applicant
• Michaelsen et al., “A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells,” Eur J Immunol., Jan. 2006;36(1):129-38.Applicant
• Mihara et al., “Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family,” Int. Immunopharmacol., 5(12):1731-40 (2005).Applicant
• Morell et al., “Metabolic properties of IgG subclasses in man,” J. Clin. Invest., 49(4):673-80 (1970).Applicant
• Morimoto et al., “Single-step purification of F(ab′)2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW,” J. Biochem. Biophys. Methods, 24:107-117 (1992).Applicant
• Murtaugh et al., “A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches,” Protein Sci., 20(9):1619-31 doi:10.1002/pro 696 (2011).Applicant
• Nakano et al., “Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors,” J. Biol. Chem., 270(11):5702-5 (1995).Applicant
• Nakano et al., “Prevention of growth arrest-induced cell death of vascular smooth muscle cells by a product of growth arrest-specific gene, gas6,” FEBS Lett., 387(1):78-80 (1996).Applicant
• Neis et al., “Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis,” J. Allergy Clin. Immunol., 118(4):930-937 (2006).Applicant
• Nemoto et al., “Overexpression of protein tyrosine kinases in human esophageal cancer,” Pathobiology., 65(4):195-203 (1997).Applicant
• Nesterova et al., “Glypican-3 as a novel target for an antibody-drug conjugate,” AACR Abstract No. 656, Los Angeles, CA (Apr. 4-18, 2007).Applicant
• Neubauer et al., “Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis,” Blood, 84(6):1931-41 (1994).Applicant
• Nishimoto et al., “Interleukin 6: from bench to bedside,” Nat. Clin. Pract. Rheumatol., 2(11):619-26 (2006).Applicant
• O'Bryan et al., “axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase,” Mol. Cell Biol., 11(10):5016-31 (1991).Applicant
• O'Shea et al., “Peptide ‘Velcro’: design of a heterodimeric coiled coil,” Curr Biol., Oct. 1, 1993;3(10):658-67.Applicant
• Ohno et al., “Antigen-binding specificities of antibodies are primarily determined by seven residues of VH,” Proc. Natl. Acad. Sci. U.S.A., 82(9):2945-9 (1985).Applicant
• Ohsugi et al., Pharm Stage, 7(5):13-18 (2007).Applicant
• Onda et al., “Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity,” Cancer Res., 61:5070-77 (2001).Applicant
• Ono et al., “The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity,” Mol. Immunol., 36(6):387-95 (1999).Applicant
• Ozhegov et al., Tolkovyi Slovar Russkogo iazyka: 2004, p. 292.Applicant
• Padlan et al., “Identification of specificity-determining residues in antibodies,” FASEB J., 9:133-139 (1995).Applicant
• Padlan et al., “Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex,” Proc. Natl. Acad. Sci. USA, 86:5938-5942 (1989).Applicant
• Pakula et al., “Genetic Analysis of Protein Stability and Function,” Annu. Rev. Genet., 23:289-310 (1989).Applicant
• Pan et al., “Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth,” Cancer Cell, Jan. 2007;11(1):53-67.Applicant
• Pardridge et al., “Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein,” J. Pharmacol. Exp. Ther., 286(1):548-54 (1998).Applicant
• Paul, “Structure and function of immunoglobulins,” Fundamental Immunology, Third Edition, 292-295 (1993).Applicant
• Pavlaki et al., “Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials,” Cancer Metastasis Rev., 22(2-3):177-203 (2003).Applicant
• Pavlinkova et al., “Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis,” Nucl. Med. Biol., 26:27-34 (1999).Applicant
• Pavlou et al., “The therapeutic antibodies market to 2008,” Eur. J. Pharm. Biopharm., 59:389-396 (2005).Applicant
• Pini et al., “Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel,” J. Biol. Chem., 273(34):21769-76 (1998).Applicant
• Poduslo et al., “Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers,” J. Neurochem., 66:1599-1609 (1996).Applicant
• Pons et al., “Energetic analysis of an antigen/antibody interface: alanine scanning mutagenesis and double mutant cycles on the HyHEL-10/lysozyme interaction,” Protein Sci., 8(5):958-68 (1999).Applicant
• Presta, “Engineering of therapeutic antibodies to minimize immunogenicity and optimize function,” Adv. Drug Deliv. Rev., 58(5-6):640-56 (2006).Applicant
• Presta et al., “Molecular engineering and design of therapeutic antibodies,” Curr. Opin. Immunol., 20(4):460-70. doi: 10.1016/j.coi.2008.06.012 (2008).Applicant
• Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc. Natl. Acad. Sci. U.S.A., 86(24):10029-10033 (1989).Applicant
• R&D Systems (R&D Systems, Anti-human IL-31 RA Antibody, Catalog #AF2769, Oct. 2008).Applicant
• R&D Systems (R&D Systems, Biotinylated Anti-human IL-31 RA Antibody, Catalog #BAF2769, Nov. 2005), 1 page.Applicant
• Raap et al., “Correlation of IL-31 serum levels with severity of atopic dermatitis,” J. Allergy Clin. Immunol., 122(2):421-423 (2008).Applicant
• Raffen et al., “Reengineering immunoglobulin domain interactions by introduction of charged residues,” Protein Eng., Apr. 1998;11:303-9.Applicant
• Rajpal et al., A general method for greatly improving the affinity of antibodies by using combinatorial libraries, Proc. Natl. Acad. Sci. USA, 102:8466-71 (2005).Applicant
• Rathanaswami et al., “Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8,” Biochem. Biophys. Res. Commun., 334:1004-13 (2005).Applicant
• Reddy et al., “Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4,” J. Immunol., 164(4):1925-33 (2000).Applicant
• Reichert et al., “Monoclonal antibody successes in the clinic,” Nat. Biotechnol., 23:1073-78 (2005).Applicant
• Reichert et al., “Development trends for monoclonal antibody cancer therapeutics,” Nat. Rev. Drug Discov., 6(5):349-56 (2007).Applicant
• Reist et al., “Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent,” Clin Cancer Res., Oct. 1998;4(10):2495-502.Applicant
• Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Eng., 9:617-621 (1996).Applicant
• Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,” Proc Natl Acad Sci U.S.A., 91:969-73 (1994).Applicant
• Roitt et al., Immunology, M., Mir, 5th Edition (2000), pp. 97-113.Applicant
• Roitt et al., Immunology, M., Mir, (2000), pp. 110, 150, and 537-9 (in Russian, with what is believed to be a published English equivalent of those pages).Applicant
• Roitt et al., Immunology, M., Mir, (2000), pp. 110-111 (in Russian, with what is believed to be a published English equivalent of those pages taken from Roitt et al., “Antibody Structure and Function,” Immunology, Fifth Ed., (1998), pp. 80-81).Applicant
• Rothe et al., “Ribosome display for improved biotherapeutic molecules,” Expert Opin. Biol. Ther., 6(2):177-87 (2006).Applicant
• Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. U.S.A., 79(6):1979-83 (1982).Applicant
• Ruf et al., “Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catuniaxomab,” J. Clin. Oncol., 26 (May 20 suppl) (2008), abstr 14006.Applicant
• Sainaghi et al., “Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor,” J. Cell. Physiol., 204(1):36-44 (2005).Applicant
• Salfeld et al., “Isotype selection in antibody engineering,” Nat. Biotechnol., 25(12):1369-72 (2007).Applicant
• Sal-Man et al., “Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive homodimer dissociation and heterodimer association in vivo,” Biochem. J., 385:29-36 (2005).Applicant
• Sarmay et al., “Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor,” Mol. Immunol., 29(5):633-9 (1992).Applicant
• Sato et al., “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth,” Cancer Res., 53(4):851-6 (1993).Applicant
• Sawabu et al., “Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway,” Mol. Carcinog., 46(2):155-64 (2007).Applicant
• Schaeffer et al., “The Rat Glomerular Filtration Barrier Does Not Show Negative Charge Selectivity,” Microcirculation, 9:329-342 (2002).Applicant
• Schmitz et al., “Phage display: a molecular tool for the generation of antibodies—a review,” Placenta., 21 Suppl A:S106-12 (2000).Applicant
• Sebba et al., “Tocilizumab: the first interleukin-6-receptor inhibitor,” Am J Health Syst Pharm., Aug. 1, 2008;65(15):1413-8. doi: 10.2146/ajhp070449.Applicant
• Segal et al., “Bispecific antibodies in cancer therapy,” Curr. Opin. Immunol., 11:558-562 (1999).Applicant
• Shaul, “Exploring the charge space of protein-protein association: a proteomic study,” Proteins, 60:341-352 (2005).Applicant
• Shieh et al., “Expression of axl in lung adenocarcinoma and correlation with tumor progression,” Neoplasia., 7(12):1058-64 (2005).Applicant
• Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J. Biol. Chem., 276:6591-6604 (2001) (Epub Nov. 28, 2000).Applicant
• Shire et al., “Challenges in the development of high protein concentration formulations,” J. Pharm. Sci., 93(6):1390-402 (2004).Applicant
• Singer et al., Genes & Genomes 1:63 (1998).Applicant
• Singer et al., Genes & Genomes, 1991; 67-69.Applicant
• Singer et al., Genes & Genomes, 1998;1:63-64.Applicant
• Sinha et al., “Electrostatics in protein binding and function,” Curr. Protein Pept. Sci., 3(6):601-14 (2002).Applicant
• Smans et al., “Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens,” Int. J. Cancer, 83:270-277 (1999).Applicant
• Sonkoly et al., “IL-31: a new link between T cells and pruritus in atopic skin inflammation,” J. Allergy Clin. Immunol., 117:411-417 (2006).Applicant
• Spiess et al., “Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies,” Nat Biotechnol., Aug. 2013; 31(8):753-8. doi: 10.1038/nbt.2621. Epub Jul. 7, 2013.Applicant
• Staerz et al., “Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity,” Proc Natl Acad Sci U.S.A., 83:1453-7 (1986).Applicant
• Strand et al., “Biologic therapies in rheumatology: lessons learned, future directions,” Nat. Rev. Drug Discov., 6(1):75-92 (2007).Applicant
• Stenhoff et al., “Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts,” Biochem. Biophys. Res. Commun., 319(3):871-8 (2004).Applicant
• Sun et al., “Coexpression of Gas6/Axl in human ovarian cancers,” Oncology, 66(6):450-7 (2004).Applicant
• Suresh et al., “Bispecific monoclonal antibodies from hybrid hybridomas,” Methods Enzymol., 1986;121:210-228.Applicant
• Takkinen et al., “Affinity and Specificity Maturation by CDR Walking,” Antibody Engineering, Springer Lab Manuals, pp. 540-545 (2001).Applicant
• Tan et al., “Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility,” Immunotechnology, 4(2):107-114 (1998).Applicant
• Tarditi et al., “Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies,” J. Chromatogr., 599:13-20 (1992).Applicant
• Teeling et al., “The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20,” J. Immunol., 177(1):362-71 (2006).Applicant
• Ten Kate et al., “Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111-labelled IgG,” Eur. J. Nucl. Med., 17:305-309 (1990).Applicant
• Thies et al., “The alternatively folded state of the antibody C(H)3 domain,” J. Mol. Biol., 309(5):1077-85 (2001).Applicant
• Tsubaki et al., “C-terminal modification of monoclonal antibody drugs: amidated species as a general product-related substance,” Int J Biol Macromol., 52:139-47. doi: 10.1016/j.ijbiomac.2012.09.016. Epub Sep. 25, 2012.Applicant
• Tsuchiya, Credit Suisse Seminar, “Therapeutic Antibody,” at Fuji-Gotemba Laboratories, p. 21 (2006).Applicant
• Tsurushita et al., “Design of humanized antibodies: From anti-Tac to Zenapax,” Methods, 36:69-83 (2005).Applicant
• Vaisitti et al., “Cationization of monoclonal antibodies: another step towards the “magic bullet”?,” J. Biol. Regul. Homeost. Agents., 19(3-4):105-12 (2005).Applicant
• Vajdos et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” J. Mol. Biol., 320(2):415-28 (2002).Applicant
• Vajkoczy et al., “Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival,” Proc. Natl. Acad. Sci. U.S.A., 103(15):5799-804 (2006).Applicant
• Van Loghem et al., “Staphylococcal protein A and human IgG subclasses and allotypes,” Scand. J. Immunol., 15(3):275-8 (1982).Applicant
• Van Walle et al., Immunogenicity screening in protein drug development, Expert Opin. Biol. Ther., 7(3):405-18 (2007).Applicant
• Varnum et al., “Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6,” Nature, 373(6515):623-6 (1995).Applicant
• Wally et al., “Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappal light chain,” Biochim Biophys Acta., May 31, 1999;1454(1):49-56.Applicant
• Wang et al., “Conserved amino acid networks involved in antibody variable domain interactions,” Proteins, Jul. 2009;76(1):99-114. doi: 10.1002/prot.22319.Applicant
• Wang et al., “Polyethylene Glycol-modified Chimeric Toxin Composed of Transforming Growth Factor alpha and Pseudomonas Exotoxin,” Cancer. Res., 53:4588-4594 (1993).Applicant
• Warnaar et al., “Purification of bispecific F(ab′)2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer,” Hybridoma, 13:519-526 (1994).Applicant
• Wiens et al., “Somatic mutation in VH complementarity-determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion,” J. Immunol., 159(3):1293-302 (1997).Applicant
• Wiens et al., “Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect,” J. Immunol., 167(4):2179-86 (2001).Applicant
• Winkler et al., “Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody,” J. Immunol., 165:4505-14 (2000).Applicant
• Wu et al., “Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract,” J. Mol. Biol., 368(3):652-65 (2007).Applicant
• Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J. Mol. Biol., 294(1):151-62 (1999).Applicant
• Wypych et al., “Human IgG2 antibodies display disulfide-mediated structural isoforms,” J. Biol. Chem., 283(23):16194-16205 (2008).Applicant
• Xiang et al., “Study of B72.3 combining sites by molecular modeling and site-directed mutagenesis,” Protein Eng., 13(5):339-44 (2000).Applicant
• Yagi et al., “Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts,” Int. J. Mol. Med., 19(6):941-946 (2007).Applicant
• Yamagata et al., “Synaptic adhesion molecules,” Curr. Opin. Cell Biol., 15(5):621-32 (2003).Applicant
• Yamasaki et al., “Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors,” J. Pharmacol. Exp. Ther., 301:467-477 (2002).Applicant
• Yang et al., “Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation,” Protein Eng., 16:761-770 (2003).Applicant
• Yang et al., “CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range,” J. Mol. Biol., 254(3):392-403 (1995).Applicant
• Zhu et al., “MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells,” J. Immunol., 166(5):3266-76 (2001).Applicant
• Zuckier et al., “Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life,” Cancer Res., 58:3905-08 (1998).Applicant
• Zwick et al., “The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5,” J. Virol., 78(6):3155-61 (2004).Applicant
• International Search Report for App. Ser. No. PCT/JP2008/067483, dated Oct. 21, 2008, 2 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2008/067483, dated Apr. 7, 2010, 13 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2009/066590, dated Oct. 20, 2009, 2 pages.Applicant
• International Preliminary Report on Patentability for PCT App. Ser. No. PCT/JP2008/067499, dated Apr. 7, 2010, 6 pages.Applicant
• Examiner Dong Jiang, USPTO Restriction Requirement in U.S. Appl. No. 12/680,112, dated Oct. 7, 2011, 6 pages.Applicant
• Fish & Richardson P.C., Amendment and Response to Species Election Requirement dated Oct. 7, 2011 in U.S. Appl. No. 12/680,112, filed Dec. 6, 2011, 15 pages.Applicant
• Examiner Dong Jiang, USPTO Non Final Office Action in U.S. Appl. No. 12/680,112, dated Feb. 29, 2012, 8 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action of Feb. 29, 2012 in U.S. Appl. No. 12/680,112, filed Aug. 27, 2012, 12 pages.Applicant
• Examiner Dong Jiang, USPTO Restriction Requirement in U.S. Appl. No. 12/680,112, dated Sep. 19, 2012, 6 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Restriction Requirement dated Sep. 19, 2012 in U.S. Appl. No. 12/680,112, filed Oct. 17, 2012, 13 pages.Applicant
• Examiner Dong Jiang, USPTO Non Final Office Action in U.S. Appl. No. 12/680,112, dated Feb. 4, 2013, 9 pages.Applicant
• Examiner Bradley Duffy, USPTO Restriction Requirement in U.S. Appl. No. 12/680,082, dated Jun. 6, 2012, 12 pages.Applicant
• Fish & Richardson P.C., Fourth Preliminary Amendment and Response to Restriction Requirement dated Jun. 6, 2012 in U.S. Appl. No. 12/680,082, filed Jun. 29, 2012, 13 pages.Applicant
• Examiner Bradley Duffy, USPTO Restriction Requirement in U.S. Appl. No. 12/680,082, dated Sep. 14, 2012, 6 pages.Applicant
• Fish & Richardson P.C., Amendment and Response to Election Requirement dated Sep. 14, 2012 in U.S. Appl. No. 12/680,082, filed Nov. 8, 2012, 14 pages.Applicant
• Examiner Bradley Duffy, USPTO Non-Final Office Action in U.S. Appl. No. 12/680,082, dated Feb. 14, 2013, 12 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Non-Final Office Action dated Feb. 14, 2013 in U.S. Appl. No. 12/680,082, filed Aug. 12, 2013, 17 pages.Applicant
• Examiner Bradley Duffy, USPTO Final Office Action in U.S. Appl. No. 12/680,082, dated Oct. 22, 2013, 12 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Final Office Action dated Oct. 22, 2013 in U.S. Appl. No. 12/680,082, filed Feb. 21, 2014, 14 pages.Applicant
• Examiner Bradley Duffy, USPTO Interview Summary in U.S. Appl. No. 12/680,082, dated Feb. 25, 2013, 3 pages.Applicant
• Examiner Bradley Duffy, USPTO Non-Final Office Action in U.S. Appl. No. 12/680,082, dated Feb. 5, 2015, 9 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Non-Final Office Action dated Feb. 5, 2015 in U.S. Appl. No. 12/680,082, filed Apr. 29, 2015, 13 pages.Applicant
• Examiner Bradley Duffy, USPTO Final Office Action in U.S. Appl. No. 12/680,082, dated May 13, 2015, 10 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Final Office Action dated May 13, 2015 in U.S. Appl. No. 12/680,082, filed Sep. 25, 2015, 18 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Restriction Requirement in U.S. Appl. No. 13/257,112, dated Oct. 15, 2013, 10 pages.Applicant
• Fish & Richardson P.C., Amendment and Response to Election Requirement dated Oct. 15, 2013 in U.S. Appl. No. 13/257,112, filed Nov. 15, 2013, 6 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Non-Final Office Action in U.S. Appl. No. 13/257,112, dated Jan. 30, 2014, 18 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Non-Final Office Action dated Jan. 30, 2014 in U.S. Appl. No. 13/257,112, filed Jul. 1, 2014, 12 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Final Office Action in U.S. Appl. No. 13/257,112, dated Sep. 5, 2014, 16 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Final Office Action dated Sep. 5, 2014 in U.S. Appl. No. 13/257,112, filed Feb. 5, 2015, 6 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Notice of Allowance in U.S. Appl. No. 13/257,112, dated Feb. 23, 2015, 8 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Notice of Allowance in U.S. Appl. No. 13/257,112, dated Apr. 2, 2015, 7 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Notice of Allowance in U.S. Appl. No. 13/257,112, dated Aug. 26, 2015, 7 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2010/054769, dated Apr. 20, 2010, 4 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2010/054769, dated Oct. 18, 2011, 6 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Restriction Requirement in U.S. Appl. No. 13/257,145, dated Mar. 20, 2013, 11 pages.Applicant
• Fish & Richardson P.C., Preliminary Amendment and Response to Restriction Requirement dated Mar. 20, 2013 in U.S. Appl. No. 13/257,145, filed Apr. 22, 2013, 7 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Non-Final Office Action in U.S. Appl. No. 13/257,145, dated Jul. 2, 2013, 20 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Office Action dated Jul. 2, 2013 in U.S. Appl. No. 13/257,145, filed Dec. 2, 2013, 12 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Final Office Action in U.S. Appl. No. 13/257,145, dated Feb. 6, 2014, 12 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Office Action dated Feb. 6, 2014 in U.S. Appl. No. 13/257,145, filed May 6, 2014, 10 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Notice of Allowance in U.S. Appl. No. 13/257,145, dated Oct. 1, 2014, 9 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Notice of Allowance in U.S. Appl. No. 13/257,145, dated Jan. 9, 2015, 7 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Notice of Allowance in U.S. Appl. No. 13/257,145, dated Mar. 11, 2015, 7 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2010/054767, dated Jun. 15, 2010, 7 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2010/054767, dated Oct. 18, 2011, 12 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2008/067534, dated Oct. 21, 2008, 4 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2008/067534, dated Apr. 7, 2010, 7 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2009/057309, dated Jul. 7, 2009, 8 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2009/057309, dated Nov. 30, 2010, 7 pages.Applicant
• European Search Report for App. Ser. No. EP 09 72 9337, dated Nov. 3, 2011, 3 pages.Applicant
• Examiner Meera Natarajan, USPTO Restriction Requirement in U.S. Appl. No. 12/295,039, dated Oct. 12, 2010, 9 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Oct. 12, 2010 in U.S. Appl. No. 12/295,039, filed Apr. 11, 2011, 9 pages.Applicant
• Examiner Meera Natarajan, USPTO Non-Final Office Action in U.S. Appl. No. 12/295,039, dated Jun. 28, 2011, 9 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Jun. 28, 2011 in U.S. Appl. No. 12/295,039, filed Dec. 27, 2011, 14 pages.Applicant
• Examiner Meera Natarajan, USPTO Final Office Action in U.S. Appl. No. 12/295,039, dated Apr. 12, 2012, 8 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Apr. 12, 2012 in U.S. Appl. No. 12/295,039, filed Sep. 11, 2012, 12 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/057036, dated Oct. 21, 2008, 6 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2007/057036, dated May 1, 2007, 2 pages.Applicant
• European Search Report for App. Ser. No. 07 74 0494, dated Sep. 3, 2009, 3 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/057058, dated Oct. 21, 2008, 11 pages.Applicant
• International Search Report App. Ser. No. PCT/JP2007/057058, dated May 7, 2001, 2 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Restriction Requirement in U.S. Appl. No. 12/295,075, dated Feb. 22, 2011, 9 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Feb. 22, 2011 in U.S. Appl. No. 12/295,075, filed Aug. 18, 2011, 2 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Non-Final Office Action in U.S. Appl. No. 12/295,075, dated Nov. 4, 2011, 14 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Nov. 4, 2011 in U.S. Appl. No. 12/295,075, filed May 3, 2012, 12 pages.Applicant
• Examiner Lynn Anne Bristol, USPTO Final Office Action in U.S. Appl. No. 12/295,075, dated Jul. 19, 2012, 12 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Jul. 19, 2012 in U.S. Appl. No. 12/295,075, filed Jan. 17, 2013, 113 pages.Applicant
• Examiner Nelson B. Moseley II, USPTO Non-Final Office Action in U.S. Appl. No. 12/295,075, dated Jun. 7, 2013, 17 pages.Applicant
• Examiner Bradley Duffy, USPTO Restriction Requirement in U.S. Appl. No. 11/910,128, dated Jun. 9, 2011, 10 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Jun. 9, 2011 in U.S. Appl. No. 11/910,128, filed Dec. 2, 2011, 1 page.Applicant
• Examiner Stephen L. Rawlings, USPTO Non-Final Office Action in U.S. Appl. No. 11/910,128, dated Apr. 25, 2012, 21 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Office Action dated Apr. 25, 2012 in U.S. Appl. No. 11/910,128, filed Oct. 25, 2012, 32 pages.Applicant
• Fish & Richardson P.C., Supplemental Amendment in U.S. Appl. No. 11/910,128, filed Nov. 14, 2012, 20 pages.Applicant
• Examiner Stephen L. Rawlings, USPTO Final Office Action in U.S. Appl. No. 11/910,128, dated Sep. 10, 2013, 12 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2009/066590, dated May 10, 2011, 6 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2009/070376, dated Jul. 5, 2011, 11 pages.Applicant
• Examiner Dong Jiang, USPTO Non-Final Office Action U.S. Appl. No. 12/680,087, dated Oct. 27, 2011, 6 pages.Applicant
• Fish & Richardson P.C., Amendment and Reply to Action dated Oct. 27, 2011 in U.S. Appl. No. 12/680,087, filed Jan. 26, 2012, 6 pages.Applicant
• Examiner Dong Jiang, USPTO Notice of Allowance in U.S. Appl. No. 12/680,087, dated Feb. 24, 2012, 5 pages.Applicant
• Examiner Dong Jiang, USPTO Notice of Allowance in U.S. Appl. No. 12/680,087, dated Jun. 25, 2012, 11 pages.Applicant
• Examiner Dong Jiang, USPTO Notice of Allowance in U.S. Appl. No. 12/680,087, dated Nov. 26, 2012, 7 pages.Applicant
• Examiner Dong Jiang, USPTO Notice of Allowance in U.S. Appl. No. 12/680,087, dated Apr. 15, 2013, 9 pages.Applicant
• Examiner Dong Jiang, USPTO Notice of Allowance in U.S. Appl. No. 12/680,087, dated Aug. 2, 2013, 8 pages.Applicant
• Examiner James L. Rogers, USPTO Restriction Requirement in U.S. Appl. No. 12/936,587, dated Dec. 6, 2011, 5 pages.Applicant
• Fish & Richardson P.C., Third Preliminary Amendment and Response to Restriction Requirement dated Dec. 6, 2011 in U.S. Appl. No. 12/936,587, filed Jun. 5, 2012, 7 pages.Applicant
• Examiner James L. Rogers, USPTO Restriction Requirement in U.S. Appl. No. 12/936,587, dated Jun. 25, 2012, 5 pages.Applicant
• Fish & Richardson P.C., Response to Species Election Requirement dated Jun. 25, 2012 in U.S. Appl. No. 12/936,587, filed Jul. 25, 2012, 1 page.Applicant
• Examiner James L. Rogers, USPTO Non-Final Office Action in U.S. Appl. No. 12/936,587, dated Nov. 7, 2012, 13 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2010/058166, dated Dec. 16, 2011, 15 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2010/066490, dated Nov. 9, 2010, 5 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2010/066490, dated Apr. 11, 2012, 6 pages.Applicant
• Examiner Julie Zhen Qin Wu, USPTO Restriction Requirement in U.S. Appl. No. 12/745,781, dated Sep. 4, 2012, 10 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Sep. 4, 2012 in U.S. Appl. No. 12/745,781, filed Sep. 21, 2012, 176 pages.Applicant
• Examiner Julie Zhen Qin Wu, USPTO Non-Final Office Action in U.S. Appl. No. 12/745,781, dated Oct. 18, 2012, 21 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Office Action dated Oct. 18, 2012 in U.S. Appl. No. 12/745,781, filed Apr. 17, 2013, 23 pages.Applicant
• Examiner Julie Zhen Qin Wu, USPTO Final Office Action in U.S. Appl. No. 12/745,781, dated May 21, 2013, 16 pages.Applicant
• Examiner Jessica Hope Roark, USPTO Restriction Requirement in U.S. Appl. No. 12/679,922, dated Oct. 2, 2012, 9 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Oct. 2, 2012 in U.S. Appl. No. 12/679,922, filed Nov. 1, 2012, 2 pages.Applicant
• Examiner Jessica Hope Roark, USPTO Non-Final Office Action in U.S. Appl. No. 12/679,922, dated Jan. 3, 2013, 25 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Jan. 3, 2013 in U.S. Appl. No. 12/679,922, filed Jul. 2, 2013, 18 pages.Applicant
• Examiner Jessica Hope Roark, USPTO Final Office Action in U.S. Appl. No. 12/679,922, dated Aug. 2, 2013, 12 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2010/073361, dated Aug. 14, 2012, 7 pages.Applicant
• Examiner James L. Rogers, USPTO Non-Final Office Action in U.S. Appl. No. 13/595,139, dated Nov. 14, 2012, 10 pages.Applicant
• International Search Report for App. Ser. No. PCT/JP2011/055101, dated May 10, 2011, 4 pages.Applicant
• International Preliminary Report on Patentability for App. Ser. No. PCT/JP2011/055101, dated Oct. 2, 2012, 6 pages.Applicant
• Examiner Michael D. Allen, USPTO Restriction Requirement in U.S. Appl. No. 13/497,269, dated Dec. 6, 2012, 9 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Dec. 6, 2012 in U.S. Appl. No. 13/497,269, filed May 1, 2013, 2 pages.Applicant
• Examiner Michael D. Allen, USPTO Non-Final Office Action in U.S. Appl. No. 13/497,269, dated Aug. 15, 2013, 13 pages.Applicant
• Fish & Richardson P.C., Reply to Non-Final Action dated Aug. 15, 2013 in U.S. Appl. No. 13/497,269, filed Nov. 15, 2013, 13 pages.Applicant
• Examiner Michael D. Allen, USPTO Final Office Action in U.S. Appl. No. 13/497,269, dated Mar. 14, 2014, 10 pages.Applicant
• Fish & Richardson P.C., Reply to Final Office Action dated Mar. 14, 2014 in U.S. Appl. No. 13/497,269, filed Sep. 10, 2014, 12 pages.Applicant
• Examiner Michael D. Allen, USPTO Non-Final Office Action in U.S. Appl. No. 13/497,269, dated Jun. 1, 2015, 21 pages.Applicant
• Examiner Sandra L. Wegert, USPTO Restriction Requirement in U.S. Appl. No. 12/809,138, dated Dec. 13, 2012, 8 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Dec. 13, 2012 in U.S. Appl. No. 12/809,138, filed Apr. 5, 2013, 2 pages.Applicant
• Examiner Bruce D. Hissong, USPTO Notice of Allowance in U.S. Appl. No. 12/809,138, dated Aug. 23, 2013, 9 pages.Applicant
• Examiner Bradley Duffy, USPTO Restriction Requirement in U.S. Appl. No. 13/320,317, dated Dec. 18, 2012, 13 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Dec. 18, 2012 in U.S. Appl. No. 13/320,317, filed Jan. 18, 2013, 3 pages.Applicant
• Examiner Bradley Duffy, USPTO Non-Final Office Action in U.S. Appl. No. 13/320,317, dated Dec. Apr. 25, 2013, 25 pages.Applicant
• Examiner Dong Jiang, USPTO Restriction Requirement in U.S. Appl. No. 13/524,528, dated Mar. 21, 2013, 7 pages.Applicant
• Fish & Richardson P.C., Reply to Restriction Requirement dated Mar. 21, 2013 in U.S. Appl. No. 13/524,528, filed Sep. 13, 2013, 1 page.Applicant
• Examiner Dong Jiang, USPTO Non-Final Office Action in U.S. Appl. No. 13/524,528, dated Sep. 30, 2013, 9 pages.Applicant
• Examiner Michael D. Allen, USPTO Restriction Requirement in U.S. Appl. No. 13/582,073, dated Feb. 6, 2014, 9 pages.Applicant
• Fish & Richardson P.C., Response to Restriction Requirement dated Feb. 6, 2014 in U.S. Appl. No. 13/582,073, filed Apr. 7, 2014, 1 page.Applicant
• Examiner Michael D. Allen, USPTO Non-Final Office Action in U.S. Appl. No. 13/582,073, dated Jul. 18, 2014, 10 pages.Applicant
• Fish & Richardson P.C., Amendment in Reply to Action dated Jul. 18, 2014 in U.S. Appl. No. 13/582,073, filed Jan. 20, 2015, 32 pages.Applicant
• Examiner Michael D. Allen, USPTO Final Office Action in U.S. Appl. No. 13/582,073, dated Apr. 21, 2015, 10 pages.Applicant
• U.S. Appl. No. 15/490,936, filed Apr. 19, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/562,186, filed Sep. 27, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/614,842, filed Jun. 6, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/725,692, filed Oct. 5, 2017, Igawa et al.Applicant
• U.S. Appl. No. 15/782,256, filed Oct. 12, 2017, Igawa et al.Applicant
• Akira et al., “Interleukin-6 in Biology and Medicine,” Adv Immunol., Dec. 31, 1993; 54:1-78.Applicant
• Annual Report 2012 (Integrated Edition Including CSR Report) Mar. 27, 2013, 154 pages.Applicant
• Araki et al., “Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab,” Mod Rheumatol. Jul. 2013 ;23(4) :827-31. doi: 10. 1007/s10165-012-0715-9. Epub Jul. 11, 2012.Applicant
• Aricha et al., “Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis,” J Autoimmun. Mar. 2011;36(2) :135-41. doi: 10. 1016/j. jaut. 2010. 12. 001. Epub Dec. 30, 2010.Applicant
• Arndt et al., “Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment,” Biochemistry, Sep. 15, 1998;37(37):12918-26.Applicant
• Ciiatellier et al., “Functional mapping of conserved residues located at the VL and VH domain interface of a Fab,” J. Mol. Biol., Nov. 22, 1996;264(1):1-6.Applicant
• Davies et al., “Antibody VH domains as small recognition units,” Biotechnology (N.Y.), May 1995;13(5):475-79.Applicant
• Gunawardane et al., “Agonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism,” J Biol Chem. Feb. 5, 2016;291(6):2799-811. doi: 10.1074/ibc.M11S.672790. Epub Dec. 7, 2015.Applicant
• Hattori, Introduction of ART-Ig and application to hemophilia A treatment, Chugai Seiyaku ni Okeru Dokuji no Kakushinteki Kotai Gijutsu. Dec. 2012; 18: 42-57 (with English translation).Applicant
• Hirano et al., “Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin,” Nature, 324: 73-76 (Nov. 1986).Applicant
• Hirata et al., “Characterization of IL-6 Receptor Expression by Monoclonal and Polyclonal Antibodies,” J lmmunol. Nov. 1, 1989;143(9) :2900-6.Applicant
• Huang et al., “A Monoclonal Anti-Human IL-6 Receptor Antibody Inhibits the Proliferation of Human Myeloma Cells,” Hybridoma. Oct. 1993:12(5) :621-30.Applicant
• Janeway et al., “Antigen Recognition by B-cell and T-cell Receptors,” Immunobiology, 5th edition. 2001 :Extract from Chapter 3, pp. 93-122.Applicant
• Janeway et al., “The Generation of Lymphocyte Antigen Receptors,” Immunobiology, 5th edition. 2001 :Extract from Chapter 4, pp. 123-154.Applicant
• Johnson et al., “Kabat database and its applications: 30 years after the first variability plot,” Nucleic Acids Res., Jan. 1, 2000;28(1):214-8.Applicant
• Jung et al., “The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains,” J. Mol. Biol., Jun. 8, 2001;309(3):701-16.Applicant
• Kabat et al., National Institutes of Health, Publ'n No. 91-3242, Sequences of Proteins of Immunological Interest, vol. 1, pp. 647-660 (5th ed. 1991).Applicant
• Khalifa et al., “Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context,” J. Mol. Recognit., May-Jun. 2000;13(3):127-39.Applicant
• Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J. Mol. Biol., Oct. 15, 1999;293(1):41-56.Applicant
• Kipriyanov et al., “Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies,” J. Mol. Biol., Jun. 27, 2003;330(1):99-111.Applicant
• Kontermann, “Recombinant bispecific antibodies for cancer therapy,” Acta Pharmacol Sin., Jan. 2005;26(1):1-9.Applicant
• Korn et al., “Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv,” J. Gene Med., Jun. 2004;6(6):642-51.Applicant
• Krieckaert et al., “Immunogenicity of biologic therapies—we need tolerance,” Nat. Rev. Rheumatol. Oct. 2010;6(10) :558-9. doi: 10. 1038/nrrheum. 2010. 153.Applicant
• Kumar et al., “The second PDZ domain of INAD is a type I domain involved in binding to eye protein kinase C. Mutational analysis and naturally occurring variants,” J. Biol. Chem., Jul. 6, 2001;276(27): 24971-7. Epub May 7, 2001.Applicant
• Labrijn et al., “Controlled Fab-arm exchange for the generation of stable bispecific IgG1,” Nat. Protoc. Oct. 2014; 9(10): 2450-63. doi: 10.1038/nprot.2014.169. Epub Sep. 25, 2014.Applicant
• Le Gall et al., “Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody,” Protein Eng. Des. Sel., Apr. 2004;17(4):357-66. Epub May 4, 2004.Applicant
• Liu et al., “Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association,” Biochem. J., Sep. 2001;358(Pt. 2): 511-6.Applicant
• Lotz et al., “B Cell Stimulating Factor 2/Interleukin 6 is a Costimulant for Human Thymocytes and T Lymphocytes,” J. Exp. Med., Mar. 1, 1988; 167(3): 1253-1258.Applicant
• Maity et al., “Equilibrium unfolding of dimeric and engineered monomeric forms of lambda Cro (F58W) repressor and the effect of added salts: evidence for the formation of folded monomer induced by sodium perchlorate,” Arch. Biochem. Biophys., Feb. 1, 2005;434(1):93-107.Applicant
• Murata et al., “Anti-Digoxin Fab Variants Generated by Phage Display,” Mol Biotechnol. Jun. 2013 :54 (2) :269-77. doi : 10. 1007/s12033-012-9564-1.Applicant
• Narhi et al., “Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin,” Protein Eng., Feb. 2001;14(2):135-40.Applicant
• Nieba et al., “Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment,” Protein Eng., Apr. 1997;10(4):435-44.Applicant
• Nishimoto et al., “Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,” Blood, 106(8):2627-32 (2005).Applicant
• Nohaile et al., “Altering dimerization specificity by changes in surface electrostatics,” Proc. Natl. Acad. Sci. U.S.A., Mar. 13, 2001;98(6):3109-14.Applicant
• Novick et al., “Monoclonal Antibodies to the Soluble Human IL-6 Receptor: Affinity Purification, Elisa, and Inhibition of Ligand Binding,” Hybridoma. Feb. 1991;10(1) :137-46.Applicant
• Okabe, Proprietary Innovative Antibody Engineering Technologies in Chugai Pharmaceutical: Dec. 18, 2012, 78 pages.Applicant
• Padlan et al., “X-ray crystallography of antibodies,” Adv Protein Chem., 1996;49:57-133.Applicant
• Pejchal et al., “A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies,” J Virol. Sep. 2009;83 (17): 8451-62. do i : 10. 1128/ JVI. 00685- 09. Epub Jun. 10, 2009.Applicant
• Peters et al., “Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability,” J Biol Chem. Jul. 13, 2012; 287(29): 24525-33. doi: 10.1074/jbc.M112.369744. Epub May 18, 2012.Applicant
• Pokkuluri et al., “A domain flip as a result of a single amino-acid substitution,” Structure, Aug. 15, 1998;6(8):1067-73.Applicant
• Rader et al., “A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries,” Proc. Natl. Acad. Sci. U.S.A., Jul. 21, 1998;95(15):8910-5.Applicant
• Raposo et al., “Epitope-specific antibody response is controlled by immunoglobulin Vh polymorphisms,” J Exp Med. Mar. 10, 2014:211 (3):405-11. doi : 10. 1084/ jem. 20130968. Epub Feb. 17, 2014.Applicant
• Reichert, “Antibodies to watch in 2014,” mAbs, 6(4): 799-802 (Jul./Aug. 2014).Applicant
• Taga et al., “Interleukin-6 Triggers the Association of Its Receptor with a Possible Signal Transducer, gp130,” Cell. Aug. 11, 1989; 58(3): 573-581.Applicant
• Taga et al., “Receptors for B Cell Stimulatory Factor 2,” J. Exp. Med. Oct. 1, 1987; 166(4): 967-981.Applicant
• Tan et al., “Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency,” Biophys. J., Sep. 1998;75(3):1473-82.Applicant
• Vargas-Madrazo et al., “An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues,” J. Mol. Recognit., May-Jun. 2003;16(3):113-20.Applicant
• Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,” Nature, 1989;341:544-546.Applicant
• Worn et al., “Stability engineering of antibody single-chain Fv fragments,” J. Mol. Biol., Feb. 2, 2001;305(5):989-1010.Applicant
• Wu et al., “Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange,” Protein Eng., Dec. 2001;14(12):1025-33.Applicant
• Yamasaki et al., “Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNb 2) Receptor,” Science. Aug. 1988 12:241 (4867) :825-28.Applicant
• Zhu et al., “Remodeling domain interfaces to enhance heterodimer formation,” Protein Sci., Apr. 1997;6(4):781-8.Applicant
• Examiner Lynn Anne Bristol, USPTO Advisory Action in U.S. Appl. No. 13/257,145, dated May 14, 2014, 5 pages.Applicant
• Examiner Lynn Anne Bristol, Reply to Advisory Action in U.S. Appl. No. 13/257,145 dated May 14, 2014, filed Jun. 3, 2014, 8 pages.Applicant
• Fish & Richardson P.C., Reply to Office Action dated Jun. 1, 2015 in U.S. Appl. No. 13/497,269, filed Sep. 30, 2015, 31 pages.Applicant
• Examiner Michael D. Allen, USPTO Non-Final Office Action in U.S. Appl. No. 13/497,269, dated Dec. 20, 2016, 27 pages.Applicant
• Examiner Michael D. Allen, USPTO Final Office Action in U.S. Appl. No. 13/582,073, dated May 24, 2017, 19 pages.Applicant
• U.S. Appl. No. 13/524,528, Igawa et al., filed Jun. 15, 2012 (abandoned).Applicant
• U.S. Appl. No. 12/680,112, Igawa et al., filed Jun. 23, 2010 (abandoned).Applicant
• U.S. Appl. No. 13/959,489, Igawa et al., filed Aug. 5, 2013 (abandoned).Applicant
• U.S. Appl. No. 12/745,781, Kuramochi et al., filed Sep. 13, 2010 (abandoned).Applicant
• U.S. Appl. No. 13/257,145, Igawa et al., filed Nov. 22, 2011 (abandoned).Applicant
• U.S. Appl. No. 13/518,861, Igawa et al., filed Oct. 4, 2012 (abandoned).Applicant
• U.S. Appl. No. 15/490,396, Igawa et al., filed Apr. 19, 2017.Applicant
• U.S. Appl. No. 12/295,075, Igawa et al., filed Apr. 20, 2009.Applicant
• U.S. Appl. No. 12/680,082, Igawa et al., filed Jun. 25, 2010.Applicant
• U.S. Appl. No. 14/047,316, Kuramochi et al., filed Oct. 7, 2013.Applicant
• U.S. Appl. No. 13/257,112, Igawa et al., filed Nov. 22, 2011.Applicant
• U.S. Appl. No. 13/320,317, Maeda et al., filed Feb. 1, 2012.Applicant
• U.S. Appl. No. 15/553,609, filed Aug. 25, 2017, Kakehi et al.Applicant
• U.S. Appl. No. 15/875,847, filed Jan. 19, 2018, Igawa et al.Applicant
• Geneseq Accession No. AEM45140, Feb. 22, 2007, “Light chain constant region of therapeutic human IgG antibody”, 1 page.Applicant
• Gershoni et al., “Epitope Mapping,” Biodrugs, May 2007;21(3):145-56.Applicant
• Golay et al., “Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro an in vivo assays,” Archives of Biochemistry and Biophysics 526: 146-153, 2012.Applicant
• Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential applicaton in humorally mediated autoimmune disease,” Int Immunol. Dec. 2006;18(12):1759-69. Epub Oct. 31, 2006.Applicant
• Stancovski et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth,” Proc Natl Acad Sci USA, 88: 8691-8695, 1991.Applicant
• Vaccaro et al., “Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies,” Proc Natl Acad Sci USA. Dec. 5, 2006: 103(49):18709-14. Epub Nov. 20, 2006.Applicant
• Yarilin, Fundamentals of Immunology M:Medicina, 1999, pp. 169-72, 354-8 (With English translation), 21 pages.Applicant
• U.S. Pat. No. 8,562,991, Igawa et al., issued Oct. 22, 2013.Applicant
• U.S. Appl. No. 13/524,528, Igawa et al., filed Jun. 15, 2012.Applicant
• U.S. Appl. No. 14/520,423, Igawa et al., filed Oct. 22, 2014.Applicant
• U.S. Pat. No. 9,688,762, Igawa et al., issued Jun. 27, 2017.Applicant
• U.S. Appl. No. 15/614,842, Igawa et al., filed Jun. 6, 2017.Applicant
• U.S. Appl. No. 12/680,112, Igawa et al., filed Jun. 23, 2010.Applicant
• U.S. Appl. No. 13/959,489, Igawa et al., filed Aug. 5, 2013.Applicant
• U.S. Appl. No. 15/263,617, Igawa et al., filed Sep. 13, 2016.Applicant
• U.S. Appl. No. 12/745,781, Kuramochi et al., filed Sep. 13, 2010.Applicant
• U.S. Appl. No. 14/340,883, Kuramochi et al., filed Jul. 25, 2014.Applicant
• U.S. Pat. No. 8,575,317, Kuramochi et al., issued Nov. 5, 2013.Applicant
• U.S. Pat. No. 9,399,680, Kuramochi et al., issued Jul. 26, 2016.Applicant
• U.S. Pat. No. 9,228,017, Igawa et al., issued Jan. 5, 2016.Applicant
• U.S. Appl. No. 13/257,145, Igawa et al., filed Nov. 22, 2011.Applicant
• U.S. Appl. No. 14/680,250, Igawa et al., filed Apr. 7, 2015.Applicant
• U.S. Pat. No. 9,340,615, Maeda et al., issued May 17, 2016.Applicant
• U.S. Appl. No. 13/497,269, Kuramochi et al., filed Jun. 1, 2012.Applicant
• U.S. Appl. No. 13/518,861, Igawa et al., filed Oct. 4, 2012.Applicant
• U.S. Appl. No. 15/617,008, Igawa et al., filed Jun. 8, 2017.Applicant
• U.S. Appl. No. 13/582,073, Kuramochi et al., filed Dec. 20, 2012.Applicant
• U.S. Appl. No. 15/024,063, Igawa et al., filed Mar. 23, 2016.Applicant
• U.S. Appl. No. 15/562,186, Igawa et al., filed Sep. 27, 2017.Applicant
• U.S. Appl. No. 15/553,609, Kakehi et al., filed Aug. 25, 2017.Applicant
• U.S. Appl. No. 11/910,128, Igawa et al., filed Oct. 7, 2008.Applicant
• U.S. Appl. No. 15/782,256, Igawa et al., filed Oct. 12, 2017.Applicant
• U.S. Appl. No. 12/295,039, Igawa et al., filed Jan. 20, 2009.Applicant
• U.S. Pat. No. 9,670,269, Igawa et al., issued Jun. 6, 2017.Applicant
• U.S. Appl. No. 15/490,936, Igawa et al., filed Apr. 19, 2017.Applicant
• U.S. Pat. No. 9,096,651, Igawa et al., issued Aug. 4, 2015.Applicant
• U.S. Appl. No. 14/741,786, Igawa et al., filed Jun. 17, 2015.Applicant
• U.S. Appl. No. 15/725,692, Igawa et al., filed Oct. 5, 2017.Applicant
• U.S. Appl. No. 15/875,847, Igawa et al., filed Jan. 19, 2018.Applicant